TOVX AMEX
Theriva Biologics, Inc.
1W: +7.9%
1M: -4.1%
3M: -6.0%
YTD: -7.8%
1Y: -40.8%
3Y: -98.1%
5Y: -99.8%
$0.23
+0.00 (+0.04%)
Weekly Expected Move ±8.0%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-12-14
Earliest Filing
2026-02-18
Latest Filing
target: 3
investor: 2
licensee: 1
partner: 1
Counterparties (Filed by TOVX)
7 relationshipsCompanies named in TOVX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Rasayana Therapeutics, Inc. | — | licensee | Theriva Biologics granted an exclusive worldwide license for SYN-020 to Rasayana Therapeutics. | 2026-02-18 | View |
| A.G.P./Alliance Global Partners | — | partner | Placement agent for the public offering of common stock and warrants. | 2024-09-30 | View |
| MSD Credit Opportunity Master Fund, L.P. | — | investor | Investor in private placement offering of Series C and Series D Convertible Preferred Stock. | 2022-07-29 | View |
| VCN Biosciences, S.L. | — | target | Target company acquired by Synthetic Biologics, Inc. | 2022-05-06 | View |
| VCN Biosciences, S.L. | — | target | Target company acquired by Synthetic Biologics, Inc. | 2022-03-11 | View |
| VCN Biosciences, S.L. | — | target | Target company acquired by Synthetic Biologics, Inc. in a share purchase agreement. | 2021-12-14 | View |
| Grifols Innovation and New Technologies Limited | GIKLY | investor | Majority shareholder of VCN Biosciences, S.L. receiving cash consideration and milestone payments. | 2021-12-14 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-08-06 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-04 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-07-07 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-11 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-05 | Other Events | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-17 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-09 | Other Events | View | |
| 2026-03-23 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-18 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2026-02-12 | Other Events | View | |
| 2026-01-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-29 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-15 | Other Events | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-29 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-20 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR